Pruritus
Pipeline by Development Stage
Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.
Key Trends
- HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
- Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
- Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market
Career Verdict
Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | HUMIRA (adalimumab) | AbbVie | $258M | 88% | LOE_APPROACHING | Declining | |
| 2 | VTAMA (tapinarof) | Merck & Co. | $19M | 6% | PEAK | Growing | 13.5yr |
| 3 | ORACEA (doxycycline) | Galderma | $4M | 1% | LOE_APPROACHING | Declining | 1.6yr |
Drug Class Breakdown
Patent cliff looming
Emerging innovation
Mature segment
Niche applications
Career Outlook
StableDermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.
Breaking In
Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.
For Experienced Professionals
Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.
In-Demand Skills
Best For
Hiring Landscape
Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.
By Department
Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.
Competitive Landscape
17 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 26 trials with date data
Clinical Trials (27)
Total enrollment: 3,222 patients across 27 trials
Evaluation of Post Burn Rehabilitation Population for Itch Control
Fexofenadine in Pruritic Skin Disease
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus
Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics
TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
Topical Aprepitant in Prurigo Patients
Itch Relieving Effect of Botox: a Study in Healthy Subjects
Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis
Food Effect Study of Linerixibat Tablets in Healthy Adult Participants
Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405
A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects
Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P
Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)
Gabapentin - A Solution to Uremic Pruritus?
Related Jobs in Dermatology
Specialty Sales Representative (Indianapolis, IN)
Territory Manager - Bakersfield
Process Expert (m/f/d) - Schaftenau, Tirol
Territory Manager - Chicago South
Specialty Sales Representative (Birmingham, AL - West)
District Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.